Endo signs $210 million Fortigel deal with ProStrakan
This article was originally published in Scrip
Endo Pharmaceuticals is to pay ProStrakan $210 million for the US licensing and distribution rights to the UK firm's yet to be approved 2% testosterone gel Fortigel.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.